Loeb & Loeb LLP announced that its client, Celsis In Vitro, Inc. (Celsis IVT), obtained a preliminary injunction against CellzDirect Inc. and Invitrogen Corporation (now known as Life Technologies) for infringement of the company’s LiverpoolTM patent (U.S. Patent No. 7,604,929), which relates to methods for producing multi-cryopreserved hepatocyte cells and using these products for in vitro drug metabolism studies.
The U.S. District Court for the Northern District of Illinois determined that Celsis IVT established an overwhelming likelihood that the Defendants have infringed one or more claims of the LiverpoolTM patent by performing certain processes and methods associated with the production of their multi-cryopreserved hepatocyte products and using these products to perform in vitro drug testing services. The Defendants have been preliminarily enjoined from using the claimed methods and barred from selling products produced from these methods.
Celsis IVT, a worldwide leader in life sciences products and services, is represented by patent litigator from Loeb & Loeb’s Chicago office, Adam G. Kelly.
The U.S. District Court for the Northern District of Illinois determined that Celsis IVT established an overwhelming likelihood that the Defendants have infringed one or more claims of the LiverpoolTM patent by performing certain processes and methods associated with the production of their multi-cryopreserved hepatocyte products and using these products to perform in vitro drug testing services. The Defendants have been preliminarily enjoined from using the claimed methods and barred from selling products produced from these methods.
Celsis IVT, a worldwide leader in life sciences products and services, is represented by patent litigator from Loeb & Loeb’s Chicago office, Adam G. Kelly.
